

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:                    )  
  )  
WOO    )  
  )  
Serial No. Continuation of            )  
parent appln. S.N. 09/357,570        )  
  )  
Filed: Concurrently herewith        )

For:       **ENTERIC COATED FORMULATION OF A BENZIMIDAZOLE  
DERIVATIVE AND METHOD FOR PREPARATION THEREOF**

APPENDIX B

Please amend the claims as indicated according to the July 30, 2003, revision to 37 C.F.R. § 1.121 concerning a manner for making claim amendments.

1. (Currently amended) An enteric coated formulation of a benzimidazole derivative comprising a core and ~~a film of an enteric coating agent on the surface thereof, the core~~ containing a complex of the benzimidazole derivative and an ion-exchange resin, ~~and the enteric coating agent having the degree of substitution by an acidic group of less than 30%~~ and an enteric coating on the surface of said core, said enteric coating being hydroxypropyl methylcellulose phthalate having a degree of substitution by phthalic acid group of 20 to 27% omeprazole, pantoprazole, timoprazole or picoprazole.

2. (Currently amended) The enteric coated formulation according to claim 1, wherein the benzimidazole derivative ~~is selected from the group consisting of~~ comprises omeprazole ~~7 lansoprazole, pantoprazole, timoprazole and picoprazole.~~

Claims 3-7 (Canceled)

8. (Currently amended) A method for preparation of an enteric coated formulation of a benzimidazole derivative, comprising ~~the step of~~ coating a core containing a complex of a benzimidazole derivative and an ion-exchange resin with an enteric coating agent ~~having the degree of substitution by an acidic group of less than 30% of hydroxypropyl methylcellulose phthalate having a degree of substitution by phthalic acid of 20 to 27%~~ omeprazole, pantoprazole, timoprazole or picoprazole.

9. (New) The enteric coated formulation according to claim 1, wherein the benzimidazole derivative comprises pantoprazole.

10. (New) The enteric coated formulation according to claim 1, wherein the benzimidazole derivative comprises timoprazole.

11. (New) The enteric coated formulation according to claim 1, wherein the benzimidazole derivative comprises picoprazole.